View Older Stories View More Recent Stories
-
Morgan Stanley Resumes Illumina (ILMN) at Equalweight
-
Illumina (ILMN) PT Raised to $139 at Baird
-
Illumina (ILMN) PT Raised to $177 at TD Cowen
-
Illumina (ILMN) PT Raised to $145 at Canaccord Genuity
-
Piper Sandler Reiterates Overweight Rating on Illumina (ILMN)
-
Illumina (ILMN) PT Raised to $145 at Barclays
-
Illumina (ILMN) PT Raised to $190 at Citi
-
Illumina (ILMN) Tops Q3 EPS by 26c; offers guidance
-
Illumina (ILMN) call put ratio 2.9 calls to 1 put with focus on January 165 calls as share price up 3.2%
-
HSBC Upgrades Illumina (ILMN) to Buy
-
TD Cowen Reiterates Buy Rating on Illumina (ILMN)
-
Piper Sandler Reiterates Overweight Rating on Illumina (ILMN)
-
Baird Reiterates Neutral Rating on Illumina (ILMN)
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
BofA Securities Reiterates Underperform Rating on Illumina (ILMN)
-
Leerink Partners Reiterates Outperform Rating on Illumina (ILMN)
-
Citi Reiterates Buy Rating on Illumina (ILMN)
-
Illumina (ILMN) introduces the MiSeq i100 Series
-
Illumina (ILMN) Files Mixed Shelf
-
European Court of Justice rules in favor of Illumina (ILMN) in jurisdictional appeal
-
GRAIL, Inc. (GRAL): Results of Galleri Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
-
Illumina (ILMN): FDA approves cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
-
3 ways to gain stock market exposure to the fertility theme
-
Daiwa Securities Upgrades Illumina (ILMN) to Buy (1)
-
Illumina (ILMN) PT Lowered to $164 at Scotiabank
-
Barclays Upgrades Illumina (ILMN) to Equalweight
-
Illumina (ILMN) shares gain after TD Cowen upgrade
-
TD Cowen Upgrades Illumina (ILMN) to Buy
-
Stifel Reiterates Buy Rating on Illumina (ILMN)
-
Illumina (ILMN) announces strategy to accelerate value creation
-
Illumina (ILMN) PT Raised to $126 at TD Cowen
-
Illumina (ILMN) PT Raised to $155 at Citi
-
Illumina (ILMN) Tops Q2 EPS by 25c; cuts revenue guidance
-
Piper Sandler Reiterates Overweight Rating on Illumina (ILMN)
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays
-
Life Science Tools & Diagnostics stocks: Q2 earnings preview
-
TD Cowen Reiterates Hold Rating on 10X Genomics (TXG)
-
10x Genomics (TXG) Declines After Illumina (ILMN) Acquires Fluent BioSciences
-
Illumina (ILMN) acquires Fluent BioSciences
-
Illumina (ILMN) call put ratio 1 call to 9.1 puts with focus on August 90 puts with stocks price at $107.42
-
Increasing unusual put option volume: BKR PTEN NWL TPX GLW CMG FITB ILMN SMR CC
-
Illumina (ILMN) PT Lowered to $131 at UBS
-
Illumina (ILMN) PT Lowered to $119 at Baird
-
GRAIL (GRAL) to Commence Separate Trading on Nasdaq
-
Illumina (ILMN) completes divestiture of GRAIL
-
Illumina (ILMN) Launches DRAGEN v4.3
-
Illumina (ILMN) PT Lowered to $175 at Evercore ISI
-
Midday movers: Southwest Airlines, CrowdStrike, KKR rise; AMD falls
-
CrowdSrike, KKR, and GoDaddy shares rise after S&P 500 inclusion news

